Developing new vaccines to protect against infectious diseases at home and abroad


Accueil Synopsis programme Test CME
Developing new vaccines to protect against infectious diseases at home and abroad Friday, July 9, 2021 11. Other, 1-hour Integrated Symposium 11c. Other • 2795 • 2:15 PM > 3:15 PM • Developing new vaccines to protect against infectious diseases at home and abroad • 16. Integrated Sessions – 4 11c. Other The aim is to share initial results of 2 novel vaccine candidates: a whole virus, inactivated, adjuvanted SARS-CoV-2 vaccine to prevent against COVID-19 at home and a live-attenuated, single dose vaccine for protection against chikungunya disease when travelling abroad. For VLA2001, the results of the first-in-human Phase 1/2 study evaluating three dose levels (low, medium, high) for safety, tolerability and immunogenicity in a two-dose schedule three weeks apart will be presented, plus Phase 3 design and future research priorities. Chikungunya is an emerging viral disease transmitted to humans by infected mosquitos, and cause fever to severe arthralgia. Chikungunya is a public health threat as no vaccine or drug against the virus exist. The results of a dose-escalation study with VLA1553 will be presented. A Phase 3 study in approximately 4,000 healthy adults is initiated, through a program granted as Fast Track by FDA and PRIME by EMA 2:15 PM • 2795-1 • The portfolio approach: lessons learned from the UK vaccine task forces response to COVID-19 > A. Adam FINN (Bristol) 2:25 PM • 2795-2 • Interactive questions 2:30 PM • 2795-3 • Travel and the pandemic: challenges faced by specialist travel clinics and how travel changed > T. Tomas JELINEK (Berlin) 2:40 PM • 2795-4 • Interactive questions 2:45 PM • 2795-5 • Leveraging established technologies: an inactivated vaccine candidate (VLA2001) with a novel adjuvant combination to protect against COVID-19 > A. Adam FINN (Bristol) 2:55 PM • 2795-6 • Interactive questions 3:00 PM • 2795-7 • Emerging Infectious Disease: Chikungunya as a public health threat and introduction to a novel vaccine candidate (VLA1553) > T. Tomas JELINEK (Berlin) 3:10 PM • 2795-8 • Interactive questions